Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Knowles

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
Gene Therapy|February 7, 2003
Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivoJ D Chester, W Kennedy, G D Hall, et al.
Analytical Biochemistry|August 1, 1990
Simultaneous isolation of DNA, RNA, and antigenic protein exhibiting kinase activity from small tumor samples using guanidine isothiocyanateL M Coombs, D Pigott, A Proctor, et al.
Cancer Research|January 1, 1983
Long-term organ culture of normal human bladderM A Knowles, A Finesilver, A E Harvey, et al.
Human Molecular Genetics|September 1, 1995
p16 (CDKN2) is a major deletion target at 9p21 in bladder cancerM P Williamson, P A Elder, M E Shaw, et al.
Genomics|September 23, 1997
Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancerS M Bell, M Shaw, Y S Jou, et al.
British Journal of Cancer|March 1, 1993
Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinomaL M Coombs, D A Pigott, M E Eydmann, et al.
Cell Death & Disease|February 1, 2014
The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their functionL K J Stadler, D C Tomlinson, T Lee, et al.
Oncogene|June 3, 1999
Mutation of the 9q34 gene TSC1 in sporadic bladder cancerN Hornigold, J Devlin, A M Davies, et al.
Oncogene|November 27, 2007
Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplificationC D Hurst, D C Tomlinson, S V Williams, et al.
Oncogene|October 6, 2009
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17KJ M Askham, F Platt, P A Chambers, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Gene Therapy|February 7, 2003
Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivoJ D Chester, W Kennedy, G D Hall, et al.
Analytical Biochemistry|August 1, 1990
Simultaneous isolation of DNA, RNA, and antigenic protein exhibiting kinase activity from small tumor samples using guanidine isothiocyanateL M Coombs, D Pigott, A Proctor, et al.
Cancer Research|January 1, 1983
Long-term organ culture of normal human bladderM A Knowles, A Finesilver, A E Harvey, et al.
Human Molecular Genetics|September 1, 1995
p16 (CDKN2) is a major deletion target at 9p21 in bladder cancerM P Williamson, P A Elder, M E Shaw, et al.
Genomics|September 23, 1997
Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancerS M Bell, M Shaw, Y S Jou, et al.
British Journal of Cancer|March 1, 1993
Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinomaL M Coombs, D A Pigott, M E Eydmann, et al.
Cell Death & Disease|February 1, 2014
The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their functionL K J Stadler, D C Tomlinson, T Lee, et al.
Oncogene|June 3, 1999
Mutation of the 9q34 gene TSC1 in sporadic bladder cancerN Hornigold, J Devlin, A M Davies, et al.
Oncogene|November 27, 2007
Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplificationC D Hurst, D C Tomlinson, S V Williams, et al.
Oncogene|October 6, 2009
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17KJ M Askham, F Platt, P A Chambers, et al.
Pageof 10